Iovance Biotherapeutics (IOVA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 10, 2026, with virtual attendance available for shareholders.

• Shareholders are invited to vote on key proposals, including director elections, executive compensation, and amendments to stock plans and the certificate of incorporation.

Voting matters and shareholder proposals

• Election of six directors to serve until the 2027 annual meeting.

• Advisory vote on executive compensation and on the frequency of future say-on-pay votes.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Approval sought for an amendment to the 2020 Employee Stock Purchase Plan to add 1,000,000 shares.

• Proposal to increase authorized common stock from 500,000,000 to 650,000,000 shares.

• Authorization to adjourn the meeting if more time is needed to solicit votes for the share increase proposal.

Board of directors and corporate governance

• Six nominees listed for election, including individuals with medical, legal, and financial expertise.